Ardana is an emerging pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, in order to address the areas of considerable unmet needs in this $25 billion-plus market. Since Ardana's foundation in July 2000 we have pursued a four-part strategy to create value from the business by: Maintaining a broad and balanced portfolio to manage risk, focusing on the therapeutic area of human reproductive health; Actively pursuing an in-licensing and acquisition programme for products and technologies to maintain a robust pipeline, including near-term commercial products and potential high value development candidates; Retaining value in our portfolio by building a sales and marketing capability in leading European markets, through both our own infrastructure and partnerships; and Maintaining a lean organisation by selective outsourcing in order to achieve flexibility. Ardana operates a fully integrated pharmaceutical business model from research right through to sales and marketing. Its experienced management team operates a virtual model in the areas of research, development (both pre clinical and clinical), manufacturing, regulatory and logistics using validated out-sourced suppliers to complete the work programmes designed internally. Ardana has its own salesforce in the UK and marketing partners in Europe. Currently Ardana's key customers are endocrinologists and urologists and, as the portfolio expands, the customer profile will include other reproductive health specialists such as obstetricians and gynaecologists.
http://www.oxfordbiomedica.co.uk
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company's lead product is a gene therapy for Parkinson's disease, which is expected to enter clinical development in 2005, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approx. 65 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co and Biogen Idec.
Generex Biotechnology Corporation is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its wholly owned subsidiaries include Generex Pharmaceuticals Inc., Antigen Express, Inc., Generex (Bermuda), Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc. The Company is in development stage. (Source: 10-K)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory